分享這篇:

影片總結

Moderna and Merck report positive Phase 3 melanoma results for an individualized mRNA vaccine added to Keytruda after a decade of development.

Moderna CEO Stéphane Bancel tells a16z’s Jorge Conde that Moderna and Merck’s personalized mRNA cancer treatment met its Phase 3 primary endpoint of recurrence-free survival in melanoma, and also its secondary endpoint of distant metastasis-free survival. In an earlier Phase 2 study, about 80% of patients were disease-free five years after treatment; Bancel hopes to file with regulators and make the treatment available as early as 2027. The vaccine compares tumor and healthy-cell DNA, then uses an algorithm to select up to 34 mutations and encode them in a patient-specific mRNA dose. Bancel says doses take about 42 days to produce, with a Massachusetts facility able to make tens of thousands annually. Moderna plans trials across other cancers, including lung, kidney, bladder, pancreatic and gastric cancers, while using Phase 3 patient data to improve its algorithm. He also describes future mRNA work in rare genetic liver diseases and autoimmune disease.

章節

  1. 0:00How Moderna Went From COVID to Cancer: Personalized Tumor Sequencing and Phase 3 Melanoma News
  2. 2:48The Phase 3 News: Moderna and Merck’s Melanoma Vaccine Meets Two Survival Endpoints
  3. 5:46What Is Keytruda & Why Isn't It Enough Alone? Keytruda’s 60% Five-Year Result and Targeted T Cells
  4. 9:23Preventing the Return of Cancer: The Vaccine Retrains Immunity to Recognize Missed Cancer Signals
  5. 11:16Why 20 Years and 1,000 Trials Failed Before mRNA Worked: 34 Personalized Mutations and 90% Different Antigens
  6. 15:09Inside the Algorithm: Moderna’s 10-Year-Old Neoantigen Model and Plans for Version 2.0
  7. 18:48The Operational Lift of Making a Vaccine for Every Patient: Tailored Doses Versus CAR T Cell Engineering
  8. 20:16Vein to Vein: Moderna’s 42-Day Personalized Vaccine Process and Factory-Efficiency Push
  9. 24:33Manufacturing at Scale & the COGS Question: Marlborough Capacity and Undisclosed Pricing
  10. 27:08How Do You Regulate a Medicine That's Different Every Time? Process BLA and Consistent Manufacturing
  11. 29:37Beyond Melanoma: Moderna Targets Lung, Kidney, Bladder, Pancreatic, and Gastric Cancers
  12. 35:58From COVID to Cancer to Autoimmune Disease: Moderna Advances Rare Liver and Personalized Treatments

完整分析還有什麼

12 章 · 57 個重點 · 12 段段落總結 · 心智圖

第一章預覽 · How Moderna Went From COVID to Cancer: Personalized Tumor Sequencing and Phase 3 Melanoma News

  • •Moderna compares tumor and healthy-cell DNA0:38
  • •The algorithm selects mutations to teach the immune system0:43
  • •Conde revisits Moderna’s 2020 COVID vaccine work1:20

其餘 54 個重點、段落總結與心智圖在完整分析裡。 分析這支影片,看完整內容 →

這支影片 39 分鐘,免費方案可分析 30 分鐘以內的影片;Plus 方案起可分析 2 小時以內。

這是 Tier 1 公開摘要

每章重點、段落總結、心智圖由分享者控制是否公開。想看完整分析?自己提交一支。

同頻道的其他分析

相關主題的分析